Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DJ0S
|
|||
| Drug Name |
NGM313
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
NGM Biopharmaceuticals South San Francisco, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Beta-klotho (KLB) | Target Info | Modulator | [1] |
| Fibroblast growth factor receptor 1 (FGFR1) | Target Info | Modulator | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Adherens junction | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Proteoglycans in cancer | ||||
| Prostate cancer | ||||
| Melanoma | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| FGF signaling pathway | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| Syndecan-4-mediated signaling events | ||||
| N-cadherin signaling events | ||||
| FGF signaling pathway | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| MAPK Signaling Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Signaling Pathways in Glioblastoma | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.